Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
Martin Reck, Klaus Friedrich Rabe · New England Journal of Medicine · 2017
Smoking cessation has reduced the incidence of lung cancer. The authors of this review discuss recent progress in diagnostic and treatment approaches, including molecular characterization to determine the likelihood of a response to targeted agents and immunotherapies.
Cited by 725 works. doi:10.1056/nejmra1703413
Authors
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- The blockade of immune checkpoints in cancer immunotherapy
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers